Overview: Growth Hormone Immunohistochemistry TestIntroduction: The Growth Hormone Immunohistochemistry Test detects growth hormone (GH) to diagnose pituitary tumors, causing growth issues or fatigue. Aligned with 2023 Endocrine Society guidelines, it uses immunohistochemistry for high specificity, supporting endocrine screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected pituitary tumors.
Other Names: GH IHC Assay, Pituitary Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: GH testing began in the 1980s with pituitary research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects GH to diagnose pituitary tumors, guides treatment, and evaluates patients with growth issues or fatigue.
Test Parameters: 1. Growth Hormone
Pretest Condition: No fasting required. Collect tissue via pituitary biopsy or surgery. Report history of growth issues, fatigue, or acromegaly symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document growth issues, fatigue, joint pain, or family history of pituitary disorders. Include current medications, especially growth hormone therapies.
Consent: Written consent required, detailing the tests purpose, pituitary tumor implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect GH in pituitary tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for pituitary tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive GH staining suggests GH-secreting pituitary tumors (e.g., acromegaly), guiding surgery or medical therapy. Negative staining may require further endocrine testing.
Specialist Consultation: Consult an endocrinologist or neurosurgeon for result interpretation and treatment planning.
Additional Supporting Tests: IGF-1 levels, pituitary MRI, or ACTH IHC to confirm pituitary tumor diagnosis.
Test Limitations: Not specific to one pituitary tumor type; clinical correlation is needed. Other conditions may affect staining.
References: Endocrine Society Pituitary Guidelines, 2023; Journal of Clinical Endocrinology, Fleseriu M, 2022.
